BR112022022327A2 - Moduladores de akt3 e métodos de uso dos mesmos - Google Patents

Moduladores de akt3 e métodos de uso dos mesmos

Info

Publication number
BR112022022327A2
BR112022022327A2 BR112022022327A BR112022022327A BR112022022327A2 BR 112022022327 A2 BR112022022327 A2 BR 112022022327A2 BR 112022022327 A BR112022022327 A BR 112022022327A BR 112022022327 A BR112022022327 A BR 112022022327A BR 112022022327 A2 BR112022022327 A2 BR 112022022327A2
Authority
BR
Brazil
Prior art keywords
akt3
methods
modulators
various diseases
activators
Prior art date
Application number
BR112022022327A
Other languages
English (en)
Portuguese (pt)
Inventor
KHLEIF Samir
Mkrtichyan Mikayel
Original Assignee
Georgiamune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgiamune Llc filed Critical Georgiamune Llc
Publication of BR112022022327A2 publication Critical patent/BR112022022327A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Amplitude Modulation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112022022327A 2020-05-08 2021-05-07 Moduladores de akt3 e métodos de uso dos mesmos BR112022022327A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063021797P 2020-05-08 2020-05-08
PCT/US2021/031372 WO2021226510A2 (en) 2020-05-08 2021-05-07 Akt3 modulators and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112022022327A2 true BR112022022327A2 (pt) 2023-01-03

Family

ID=78468492

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022022327A BR112022022327A2 (pt) 2020-05-08 2021-05-07 Moduladores de akt3 e métodos de uso dos mesmos

Country Status (12)

Country Link
US (1) US20230181563A1 (cg-RX-API-DMAC7.html)
EP (1) EP4146196A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023525758A (cg-RX-API-DMAC7.html)
KR (1) KR20230019109A (cg-RX-API-DMAC7.html)
CN (1) CN115956078A (cg-RX-API-DMAC7.html)
AU (1) AU2021269065A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022022327A2 (cg-RX-API-DMAC7.html)
CA (1) CA3182675A1 (cg-RX-API-DMAC7.html)
IL (1) IL297596A (cg-RX-API-DMAC7.html)
MX (1) MX2022014019A (cg-RX-API-DMAC7.html)
PH (1) PH12022553026A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021226510A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021212111A1 (en) * 2020-04-17 2021-10-21 Augusta University Research Institute, Inc. Compositions and methods for treating leukemia
US20230295114A1 (en) * 2020-05-08 2023-09-21 Georgiamune Llc Akt3 modulators
CN115867562A (zh) * 2020-05-08 2023-03-28 乔治穆内有限责任公司 Akt3调节剂

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03001256A (es) * 2000-08-11 2004-12-06 Vertex Pharma Inhibidores de p38.
DE602004026047D1 (de) * 2003-04-24 2010-04-29 Merck Sharp & Dohme Hemmer der akt aktivität
EP2078008A2 (en) * 2006-10-12 2009-07-15 SuperGen, Inc. Quinoline derivatives for modulating dna methylation
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
US7790746B2 (en) * 2007-10-12 2010-09-07 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
US7939546B2 (en) * 2007-10-12 2011-05-10 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
GB201207722D0 (en) * 2012-05-02 2012-06-13 Bergenbio As Method
US9707278B2 (en) * 2014-04-17 2017-07-18 Augusta University Research Institute, Inc. Methods of modulating immune responses by modifying Akt3 bioactivity
US10292978B2 (en) * 2016-01-15 2019-05-21 Augusta University Research Institute, Inc. Specific Akt3 inhibitor and uses thereof
US10342868B2 (en) * 2016-01-15 2019-07-09 Augusta University Research Institute, Inc. Methods and compositions for inhibiting Akt3
US20210208778A1 (en) * 2017-06-29 2021-07-08 Hewlett-Packard Development Company, L.P. Contiguous planar display operable to have area functioning as primary display and area functioning as secondary display
EP3678666B1 (en) * 2017-09-07 2025-07-09 Augusta University Research Institute, Inc. Specific akt3 activator and uses thereof

Also Published As

Publication number Publication date
US20230181563A1 (en) 2023-06-15
PH12022553026A1 (en) 2024-05-13
EP4146196A2 (en) 2023-03-15
AU2021269065A1 (en) 2022-12-15
KR20230019109A (ko) 2023-02-07
MX2022014019A (es) 2023-02-16
WO2021226510A9 (en) 2022-01-13
CA3182675A1 (en) 2021-11-11
WO2021226510A3 (en) 2021-12-16
JP2023525758A (ja) 2023-06-19
WO2021226510A2 (en) 2021-11-11
IL297596A (en) 2022-12-01
EP4146196A4 (en) 2024-06-26
CN115956078A (zh) 2023-04-11

Similar Documents

Publication Publication Date Title
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
BR112023020182A2 (pt) Métodos para tratar câncer em um sujeito em necessidade do mesmo e para inibir ras em uma célula
CO2026004964A2 (es) Moduladores de kras
CR20200653A (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
BR112022001678A2 (pt) Inibidor mek, uso de um inibidor mek, método de tratar ou reduzir o risco de desenvolver um acidente vascular cerebral em um sujeito, composição, e, kit de partes
BR112022017724A2 (pt) Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos
CL2023003068A1 (es) Compuestos, composiciones y métodos para el tratamiento de trastornos
BR112021006392A2 (pt) moduladores da alfa-1 antitripsina
BR112022017508A2 (pt) Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos
BR112023009531A2 (pt) Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos
BR112023020781A2 (pt) Moduladores de cbl-b e usos dos mesmos
BR112022008295A2 (pt) Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer
BR112018073920A2 (pt) inibidores de pd-1/pd-l1 para tratamento de câncer".
BR112022009631A2 (pt) Combinações de inibidores de dgk e antagonistas do ponto de checagem
MY197427A (en) Combination therapy for the treatment or prevention of tumours
BR112018012255A2 (pt) método para tratar câncer
BR112024001180A2 (pt) Composições e métodos para tratamento do melanoma
CO2020009731A2 (es) Inhibidor de la gremlina-1 para el tratamiento de una fractura o defecto óseos
BR112022009710A2 (pt) Terapia de combinação compreendendo um inibidor de alk2 e um inibidor de jak2
CO2022014499A2 (es) Moduladores de nlrp3
EA202192394A1 (ru) Ингибиторы пути передачи сигнала notch и их применение для лечения рака
BR112022002025A2 (pt) Composições e métodos para tratar águas residuais
JOP20250103A1 (ar) طرق للعلاج أو الوقاية من ضمور العضلات النخاعي
BR112022022305A2 (pt) Combinação farmacêutica que compreende tno155 e nazartinibe
PH12022553026A1 (en) Akt3 modulators and methods of use thereof

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: GEORGIAMUNE INC. (US)